期刊文献+

CK-19抗体在检测非小细胞肺癌淋巴结微转移中的应用 被引量:2

Anti-CK-19 and Its Use in the Detection of Micrometastasis to Lymph Nodes of NSCLC
下载PDF
导出
摘要 目的 了解角蛋白 19(CK 19)抗体在检测肺癌淋巴结微转移中的作用。方法 应用免疫组化的方法对5 0例肺癌患者的 10 6个常规病检阴性的淋巴结进行检测 ,分析相关影响因素 ,结合术前血浆肿瘤标志物浓度 ,计算出微转移危险因子 (MRF)计分。结果 CK 19抗体检测的阳性率为 11 3% (12 / 10 6 ) ,阳性病例的比例高达 2 4 %(12 / 5 0 )。单因素分析显示年龄、肿瘤解剖定位 (左 /右肺 )、大小与淋巴结微转移有关 ;多因素分析结果显示 ,淋巴结微转移的危险因子包括肿瘤解剖定位 (左 /右肺 )、大小 ,OR值分别为 1 75、 2 31。当MRF≥ 3时 ,6 2 5 % (5 / 8)发生微转移 ,而MRF <3时 ,仅 8 3% (1/ 12 )发生微转移 ,P <0 0 5。结论 CK 19抗体是检测肺癌淋巴结微转移的有效指标 ,当MRF≥ 3时应注意阴性淋巴结的微转移情况。 Objective To apply anti-cytokeratin-19 (anti-CK-19) in the detection of micrometastasis to lymph nodes of lung cancer.Methods 106 HE negative lymph nodes from 50 lung cancer patients were stained by IHC method and associated factors together with tumor markers were analyzed to calculate micrometastasis risk factors (MRF) score. Results The positive rate of anti-CK-19 stain was 11.3 % (12/106) and positive cases were 12 (24 %). Risk factors for micrometastasis obtained by univariate analysis were age, location of tumor (left vs. right), and tumor size. The significant risk factors noted by multivariate analysis were location of tumor (left vs. right), and size. 62.5 % (5/8) had micrometastasis in those with MRF≥3, compared to 8.3 % in MRF<3, P<0.05.Conclusion Anti-CK-19 is a useful marker in the detection of micrometastasis to lymph nodes of lung cancer. Further investigation should be applied to detect micrometastasis in negative lymph node when MRF≥3.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2004年第5期606-608,618,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词 淋巴结微转移 CK-19 肿瘤 抗体 解剖定位 危险因子 非小细胞肺癌 大小 角蛋白 阳性率 non-small-cell lung cancer micrometastasis of lymph nodes anti-CK-19
  • 相关文献

参考文献9

  • 1郑智,潘铁成,李军,陈涛,宋定伟,易军.Ⅰ期非小细胞肺癌淋巴结微转移与预后关系的Meta分析[J].癌症,2004,23(2):185-188. 被引量:13
  • 2Moll R, Franke W W, Schiller D L et al. The catalog of human cytokeratins: patterns of expression in normal epithelia. Cell, 1982, 31: 11
  • 3van Muijen G N P, Ruiter D J, van Leenwen C et al.Cytokeratin and neurofilament in lung carcinomas. Am J Pathol, 1984, 116: 363
  • 4Wu J, Yasuhiko O, Hiroshi M et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg, 2001,71: 1772
  • 5Toshihiro O, Tsunehiro O, Gu C D et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage Ⅰ non-small-cell lung cancer. J Clin Oncol,2002, 20:2930
  • 6Gu C D, Toshihiro O, Tsunehiro O et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer. Ann Surg, 2002, 235:133
  • 7郑如恒,葛棣,乔玉磊,石美鑫.肺癌淋巴结微转移灶检测对分期和预后的影响[J].中华肿瘤杂志,2002,24(1):41-43. 被引量:10
  • 8Hata E, Hayakawa K, Miyamoto H etal. Rationale for extended lymphadenectomy for lung cancer. Theor Surg, 1990, 5:19
  • 9Jeffrey B R, Jordan D, Hanna B R et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Surg, 1998, 116: 412

二级参考文献20

  • 1Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pNO lymph nodes of patients with completely resected nonsmall cell lung camcer: impact on recurrence and survival [J]. Ann Surg, 2002. 235(1): 133 - 139.
  • 2Wu J. Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter[J]. Ann Thorac Surg, 2001.71(6):1772- 1778.
  • 3Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastasis in the lymph nodes of patients with stage Ⅰ non-small-cell lung cancer [J]. J Thorac Cardiovac Surg, 1997, 114 (4):535 -543.
  • 4Osaki T, Oyama T. Gu CD. et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely rcsected stage Ⅰ non-small-cell lung cancer [ J ]. J Clin Oncol, 2002, 20 (13) : 2930 - 2936.
  • 5Hashimoto T, Kobayashi Y, Ishikawa Y, et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small-cell lung carcinoma cases [J] . Cancer Res, 2000, 60(22): 6472 -6478.
  • 6Kawano R, Heta E, Ikeda S, et al. Micrometastasis to lymph nodes in stage I left lung cancer patients [J]. Ann Thorac Surg, 2002,73(3): 1558 - 1562.
  • 7Ohta Y, Nozawa H, Tanaka y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased nm23 expression associated with microdissemination in the lymph nodes in stage Inon-small-cell lung cancer [J] . J Thorac Cardiovac Surg, 2000, 119(4): 804 -813.
  • 8Bostick PJ,Chatterjee S,Chi DD,et al.Limitation of specific reversetranscriptase polymerase chain reaction markers in the detection of metastasis in the lymph nodes and blood of breast cancer patients[].Journal of Clinical Oncology.1998
  • 9Dobashi K,Sugio K,Osaki T,et al.Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance[].Journal of Thoracic and Cardiovascular Surgery.1997
  • 10Sasaki M,Watanabe H,Jass JR,et al.Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: a comparison with genetic analysis of Kras[].Histopathology.1998

共引文献21

同被引文献22

  • 1廖秋林,李莲花,陈铭声.比较研究TPS、CEA、CYFRA21-1和STNFR四种肿瘤活性标志物在肺癌中的诊断价值[J].中国肺癌杂志,2005,8(4):309-312. 被引量:13
  • 2王艳,朱波,叶明福,陈正堂.非小细胞肺癌VEGF-C表达与淋巴管生成和淋巴转移关系的研究[J].中国肺癌杂志,2006,9(2):182-186. 被引量:9
  • 3于清蕊.干细胞与肿瘤干细胞[J].中国组织工程研究与临床康复,2007,11(15):2948-2951. 被引量:8
  • 4Groome PA, Bolejack V, Crowley JJ, et al. The iaslc lung Cancer Staging Project:validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol, 2007, 2 (8) : 694-705.
  • 5Goldstraw P, Crowley J, Chansky K, et al. The iaslc lung cancerstaging project: proposals for the revision of the TNM stage group- ings in the forthcoming (seventh)edition of the TNM classification of malignant turnouts. J Thorac Oncol, 2007, 2 (8) : 706-714.
  • 6Ko YH, Jung CK, MALE, et al. Clinical significance of vascular endothelial growth factors (VEGF)-C and-D in resected non-small cell lung cancer. Cancer Res Treat, 2008, 40 (3) : 133-140.
  • 7Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothe- lial growth factor C promotes tumor lymphangiogenesis and intralym- phatic tumor growth. Cancer Res, 2001, 61 (5) : 1786-1790.
  • 8Wang J, Zhang B, Guo Y, et al. Artgmisinin inhibits tumor lym- phangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology, 2008, 82 (2) : 148-155.
  • 9Liu H, Yang Y, Xiao J, et al. Inhibition of cyclooxygenase-2 sup- presses lymph node metastasis via VEGF-C. Anat Ree (Hoboken), 2009, 292(10): 1577-1583.
  • 10Shibata MA, Morimoto J, Shibata E, et al. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocom- petent mammary cancer model. Cancer Gene Ther, 2008, 15 ( 12): 776-786.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部